IE47755B1 - Derivatives of clavulanic acid and pharmaceutical compositions containing them - Google Patents

Description

The present invention relates to certain salts of some ethers of clavulanic acid, to a process for their preparation^ to compositions containing them and to their use as intermediates.

Belgian Patent No. 847045 discloses that salts of ethers of clavulanic acid may be used inter alia to enhance the effectiveness of penicillins and cephalosporins in the treatment of bacterial infections such as those caused by β-lactamase producing strains of gram-negative and gram-positive bacteria such as Klebsiella aerogenes and Staphylococcus aureus. However the previously described salts, such as the sodium or potassium salts of the said ethers, tend to have relatively poor storage properties. It has now been found that certain new salts of these ethers have improved storage properties.

In addition these new salts are useful in the preparation of the known alkali and alkaline metal salts of the ethers.

Accordingly the present invention provides the compounds of the formula (I): 47753 wherein R is a hydrogen atom or a methyl, methoxyl, hydroxymethyl, or nitrile group; R1 is a hydrogen atom or a lower alkyl, aralkyl, phenyl or inertly substituted 2 lower alkyl, aralkyl or phenyl group; R is a hydrogen atom or a lower alkyl, aralkyl, phenyl or inertly substituted lower alkyl, aralkyl or phenyl group; and 3 R is lower alkyl, aralkyl, phenyl or inertly substituted lower alkyl, aralkyl or phenyl group; any of said groups 12 3 R , R and R being optionally interlinked to form a ring of 5 - 7 ring atoms.

When used herein the term 'lower' means that the group contains up to 6 carbon atoms. When used herein the term 'aralkyl' means a lower alkyl group substituted by a phenyl or inertly substituted phenyl group.

Suitably inert substituents include halogen, and . . lower alkoxyl, lower acyloxyl,/lower esterified carboxyl groups. Suitably 1, 2 or 3 such substituent groups are present, more suitably 1 or 2 and preferably not more than one such substituent group is present.

Normally and preferably the amine of the formula (II): R I , H„N -C-R’ I 2 CH2R (II) from which the salt of the formula (I) is notionally derivable is a non-toxic amine.

Most suitably R1 is a lower alkyl group; most 2 suitably R is a hydrogen atom or a lower alkyl group; most suitably R is a lower alkyl or aralkyl group; any of said groups being linked to form a 5 - 7 membered ring.

Most suitably the compound of the formula (II) does not contain a chiral centre.

Suitably R is methoxyl. Suitably R is nitrile.

Suitably R is hydroxymethyl. More suitably R is methyl, Most suitably R is hydrogen.

Suitably the salt of the formula (I) is derivable from an amine of the formula (II) which contains 4-16 carbon atoms, more suitably 4-12 carbon atoms and preferably 4-10 carbon atoms.

Suitably the salt of the formula (I) is derivable from 2-amino-2-methylpropane, 2-amino-2-methylbutane, 2-amino-2-methylpentane, 2-amino-2-methylhexane, 2-amino-2-methylheptane, 2-amino-2-methyloctane, 3amino-3-methylpentane, 1-amino-l-methylcyclohexane, 1-amino-spiro-adamantane and other similar amines.

Most suitably the amine of the formula (II) is tertiarybutylamine (that is R3, and R^ are methyl 2 groups and R is a hydrogen atom).

From the foregoing it will be realised that one particularly suitable compound of this invention is the tertiarybutylamine salt of the methyl ether of clavulanic acid. It will also be realised that another particularly suitable compound of this invention is the tertiarybutylamine salt of the ethyl ether of clavulanic acid.

The preceding compounds are particularly suitable when crystalline.

The present invention also provides pharmaceutical compositions which comprise a compound of the formula (I) as hereinbefore defined and a pharmaceutically acceptable carrier.

The compositions of this invention may be presented in orally or parenterally or other convenient form. Generally the composition will be adapted for oral administration to a human although injectable forms and veterinary compositions may also be prepared. 7 7 5 5 Normally the composition of this invention will be in unit dosage form containing from about 20 mg to 250 mg, for example about 50, 75, 100, 125, 150 or 200 mg of a compound of the formula (I).

Such compositions will usually be administered from 2 to 6 times daily, for example 3 or 4 times daily so that the daily dose is from about 60 mg to 1000 mg, more usually from about 200 mg to about 750 mg.

Desirably the composition of this invention 10 will also comprise a penicillin or cephalosporin.

Most suitably the ratio of compound of this invention to penicillin or cephalosporin is from 1:10 to 10:1, more usually 2:1 to 1:5, for example about 1:1, 1:2, 1:3 or 1:4 (by weight).

IS Suitable penicillins and cephalosporins for inclusion in such compositions include those named in Belgian Specifications Nos. 827926 or 847045.

Particularly suitable penicillins for inclusion in the compositions of this invention include ampicillin, amoxycillin and their pro-drugs such as their in-vivo hydrolysable esters. Preferred forms of these penicillins for inclusion in the compositions of this invention include ampicillin anhydrate, ampicillin trihydrate and amoxycillin trihydrate of which amoxycillin trihydrate is preferred. Other favoured forms of the penicillins include the pharmaceutically acceptable salts of ampicillin and amoxycillin such as their sodium salts. Yet other favoured forms of the penicillins include hydrochloride or other pharmaceutically acceptable salts of the pivaloyloxymethyl, phthalidyl or a-ethoxycarbonyloxyethyl esters of ampicillin.

Other particularly suitable penicillins for inclusion in the compositions of this invention include carbenicillin, ticarcillin and their pro-drugs such as 35 their in-vivo hydrolysable esters. Suitable forms of 477 3 5 these penicillins include the di-sodium salts of carbenicillin or ticarcillin and the sodium salts of the phenyl, lower alkylphenyl or indanyl esters of carbenicillin or ticarcillin.

Penicillins suitable for inclusion in orally administrable compositions of this invention include benzylpenicillin, phenoxymethylpenicillin, propicillin, amoxycillin, ampicillin, epicillin, azidocillin, cyclacillin, and other orally active penicillins and their salts and in-vivo hydrolysable esters and aldehyde and ketone adducts of those penicillins containing a 6-a-aminoacylamido side chain and their salts.

Suitable penicillin in-vivo hydrolysable esters include the acetoxymethyl, pivaloyloxymethyl, a-ethoxycarbonyloxyethyl and phthalidyl esters of ampicillin or amoxycillin or the phenyl tolyl and indanyl α-esters of carbenicillin and ticarcillin and salts thereof. Suitable aldehyde and ketone adducts of penicillins containing a 6-aaminoacylamido side chain include the formaldehyde and acetone adducts metampicillin and hetacillin and their salts. Suitable penicillins for inclusion in injectably or infusably administrable compositions include the acceptable salts of benzylpenicillin, phenoxymethylpenicillin, carbenicillin, propicillin, azidocillin, ampicillin, amoxycillin, epicillin, azlocillin, mezlocillin, ticarcillin, cyclacillin and other known penicillins.

Cephalosporins suitable for inclusion in orally administrable compositions of this invention include cephalexin, cephradine, cephaloglycine, cephaparole and their salts and other known cephalosporins and their salts and in-vivo hydrolysable esters and aldehyde and ketone adducts of those cephalosporins containing a 7-a-aminoacylamido side chain and their salts. Suitable cephalosporins for inclusion in the injectable or infusable compositions of this invention include the salts of cephaloridine, cephalothin, cefazolin, cephalexin, 7 7 5 5 cephacetril cephamandole, cephapirin, cefuroxime, cephradine, cephaloglycine, cephatrizine, and other known cephalosporins.

Particularly suitable forms of the compositions of this invention are those which do not contain high levels of residual water. Most suitably such compositions are prepared from dry materials so that the final compositions contain less than 5% moisture, more suitably less than 3% moisture and preferably less than 2% moisture, for example 1% or less of moisture.

Most suitably the compositions of this invention are packaged in moisture-excluding forms such as closed containers, foil lined packs and the like. Such packs may also contain a desiccant such as silica gel or a molecular sieve.

The present invention also provides a process for the preparation of the compounds of the formula (I) which process comprises the reaction of a compound of the formula (III): wherein R is as defined in relation to formula (I), with a compound of the formula (II): h2n C - RI 2 CH2R 3 wherein R , R and R are as defined in relation to formula (I).

(II) The neutralisation of the acid (III) with the amine (II) may be brought about under conventional conditions for such reactions, for example the reaction is performed at a non-extreme temperature (usually from about 0° to 30°C, e.g. 15-25°C) and in an inert organic solvent such as an ether, halohydrocarbon, ketone or ester solvent, for example tetrahydrofuran, diethylether, methylene dichloride, chloroform, acetone, ethyl acetate or mixtures of such solvents.

The desired salt can generally be recovered from the reaction mixture by filtration (after concentration if necessary). The salt may then be dried for example in vacuo. If desired the salt may be recrystallised, for example from a lower alkanol such IS as ethanol. One crystallisation is generally sufficient to yield a salt of at least 95% purity (weight/weight).

The present invention also provides a process for the preparation of a salt of the formula (I) which process comprises the displacement of an alternative cation from an alternative salt of a compound of the formula (III) by a protonated amine of the formula (II). Normally this will involve the use of a salt of the amine with a cation exchange resin.

Suitable cation exchange resins for use in this process are cross-linked polystyrene-divinylbenzene co-polymers substituted by acid groups in the form of the desired amine of the formula (II) salt.

The preferred acid group is the sulphonic acid group.

The resins chosen will generally have 2-20% crosslinking and usually 4-10% cross-linking for example about 8% cross-linking. The resin is usually in the form of beads, for example spherical beads of 14-52 OK mesh size.

Suitable resins include the desired amine salt (e.g. t-butylamine) form of Amberlite resins such as IR-120, IR-121, IR-122, 200, 200C, 252; Dowex resins such as 50WX1, 50WX2, 50X4, 50WX8, 5X10, WX10, 5OWX16; Bio Rad resins such as AG 50WX1, 40WX2, AG 5OWX4, AG 50WX8, AG 50WX12; Ionac resins such as C250, C258 or C255 and Zerolit resins such as 225, 325, 425, 525, 625; etc.

The resin is normally used in large excess. The quantity of resin used should be sufficient to provide an exchange capacity at least 10 times, more suitably at least 20 times and preferably at least 30 times of the total cations applied to the solution of the salt of clavulanic acid ether.

In use the resin is in a bed through which the solution is percolated. Generally this bed is in the form of a column.

The concentration of the solution of the salt to be exchanged is not critical but very dilute solutions (for example, less than 1% w/v) should be avoided as low concentrations can lead to inconveniently low loading and incomplete exchange. Simiarly very high concentrations (for example those approaching saturation) should be avoided as such solutions can have too high a viscosity for easy use. In general for most salts concentration 2-30% w/v are acceptable, a range of about 5 to 25% being more suitable and a range of about 8 to 20% being preferred, for example about 10%.

The solution to be exchanged is normally applied slowly to the top of the column. The band is then allowed to percolate slowly into the top of the resin after which a little water is applied to wash the band a short way into the resin. The remaining necessary water is then slowly run through the column so that the band passes through the column in as tight a band as conveniently possible. 755 The presence of the desired salt in the eluate is usually readily detectably by a change in the refractive index of the eluate. This may be determined using a refractometer or visually, for example by the presence of striations. Alternatively fractions may be taken and tested in convenient manner, for example by spotting on a thin layer chromatography plate and spraying with permanganate which is decoloured by the β-lactam containing compound or by methods using the enzyme inhibitory effects of the material.

The desired salt of the amine of formula (I) may be obtained from solution in conventional manner, for example from a relatively concentrated solution by the slow addition of a water miscible organic solvent such as acetone until crystallisation commences or by concentrating under reduced pressure to a syrup followed by adding small quantities of acetone, acetonitrile, acetone/ether or the like to initiate crystallisation.

The present invention provides a process for the preparation of the sodium, potassium, calcium or magnesium salt of a compound of the formula (III) which process comprises the reaction of a compound of the formula (I) with a sodium, potassium, calcium or magnesium salt of a cation exchange resin.

Suitable cation exchange resins for use in this process are cross-linked polystyrene-divinylbenzene co-polymers substituted by acid groups in the form of the desired alkali metal or alkaline earth metal salt. The preferred acid group is the sulphonic acid group.

The resins chosen will generally have 2-20% crosslinking and usually 4-10% cross-linking for example about 8% cross-linking. The resin is usually in the form of beads, for example spherical beads of 14-52 U.K. size.

Suitable resins include the desired alkali metal or alkaline earth metal form of Amberlite resins such as IR-120, IR-121, IR-122, 200, 200C, 252; Dowex resins such as 50WX1, 50WX2, 50X4, 50WX8, 5X10, WX10, 50WX16; Bio Rad resins such as AG 50WX1, 40WX2, AG 50WX4, AG 50WX8, AG 5OWX12; Ionac resins such as C250, C258 or C255 and Zerolit resins such as 225, 325, 425, 525, 625; The resin is normally used in large excess. The quantity of resin used should be sufficient to provide an exchange capacity at least 10 times, more suitably at least 20 times and preferably at least 30 times of the total cations applied to the solution of the salt of clavulanic acid ether.

In use the resin is in a bed through which the solution is percolated. Generally this bed is in the form of a column.

The concentration of the solution of the salt to be exchanged is not critical but very dilute solutions (for example, less them 1% w/v) should be avoided as low concentrations can lead to inconveniently low loading and incomplete exchange. Simiarly very high concentrations (for example those approaching saturation) should be avoided as such solutions can have too high a viscosity for easy use. In general for most salts concentration 2-30% w/v are acceptable, a range of about 5 to 25% being more suitable and a range of about 8 to 20% being preferred, for example about 10%.

The solution to be exchanged is normally applied slowly to the top of the column. The band is then allowed to percolate slowly into the top of the resin after which a little water is applied to wash the band a short way into the resin. The remaining necessary water is then slowly run through the column so that the band passes through the column in as tight a band as conveniently possible.

The presence of the desired salt in the eluate is usually readily detectably by a change in the refractive index of the eluate. This may be determined using a refractometer or visually, for example by the presence of striations. Alternatively fractions may be taken and tested in convenient manner, for example by spotting on a thin layer chromatography plate and spraying with permanganate which is decoloured by the β-lactam containing compound or by methods using the enzyme inhibitory effects of the material.

The desired alkali metal or alkaline earth metal salt may be obtained from solution in conventional manner, for example from a relatively concentrated solution by the slow addition of a water miscible organic solvent such as acetone until crystallisation commences or by concentrating under reduced pressure to a syrup followed by adding small quantities of acetone, acetonitrile, acetone/ether or the like to initiate crystallisation.

Most suitably crystallisation is initiated at an ambient or slightly elevated temperature, for example, 12-30°C, more suitably 20-25°C. Once crystallisation has begun the mixture may be cooled, for example to about -5°C to -10°C until no further crystals appear.

Once the desired crystals have formed they may "be filtered off and dried. Vigorous drying conditions (such as vacuum drying) are best avoided as they tend to lead to breakdown of the crystal structure and partially dehydrated crystals. Wet air should not be used for drying as it can lead to wet crystals. Drying should be effected at atmospheric pressure.

The alkali metal and alkaline earth metal salts when produced by the process of this invention are also aspects of this invention. 7 7 5 5 Suitably the preceding process preparation of a sodium salt.

Suitably the preceding process the preparation of a potassium salt.

Suitably the preceding process the preparation of a calcium salt.

Suitably the preceding process the preparation of a magnesium salt. is adapted to the is adapted to is adapted to is adapted to Example 1 Preparation of t-butylamine jsalt of O-methyl clavulanic acid p-Methoxybenzyl O-methyl clavulanate (20g) in tetrahydrofuran (200 ml) was hydrogenated at 5 p.s.i. in the presence of 10% palladium on charcoal. The catalyst was filtered off and the filtrate evaporated until solid just appeared. Fresh tetrahydrofuran was added dropwise until the solid just redissolved and the solution diluted with ether (500 ml). The solution was stirred and t-butylamine (4.4. g) was added dropwise. After stirring for a further 2 hours at ambient temperature, the solid was filtered off, washed with ether and dried in vacuo to yield crude t-butylamine O-methyl clavulanate (15.2 g). This material was recrystallised from ethanol (150 ml) and ether (750 ml) to yield pure crystallin t-butylamine O-methyl clavulanate (11.9 g). (Puritv 97.5% by imidazole assay, 95 .7% by h, ,p.l.c. assay· Moisture 0.4%). X. r (major peaks) = 2650, 2530, 1784, 1692, 1640, 1570, 1400, 1391, 1296, 1279, 1188, 1147, 1075, 1015, 902, 736 cm. 20 CuKx (x-ray major peaks) = 10.9 12.2 13.2 15.2 16.7 17.6 18.3 19.2 19.8 20.7 22.1 23.0 24.5 25.2 26.6 7 7 5 5 Example 2 Preparation of the t-butylamine salt of O-methylclavulanic acid The benzyl ester of O-methylclavulanic acid 5 (39.2 g, 0.129 mole) in THF (400 ml) was hydrogenated at ca 5 psi in the presence of 10% Pd/C (13 g) until completion (ca 40 mins). The mixture was filtered through Celite and the resultant solution evaporated to a solid. This was dissolved in the minimum quantity °f THF and diluted with ether (11). To this stirred solution was added t-butylamine (9.45 g, 0.129 mole) and crystallization occured in a short time. After one hour the solid was filtered off, washed with ether and dried in vacuo. Reerystallization from ethanol/ ether afforded 27.1 g (73%) of white material of ?95% purity. 7 7 5 5 ΙΟ Example 3 Preparation of the t-butylamine salt of O-ethylclavulanic acid The p-methoxybenzyl ester of O-ethylclavulanic acid (47 g, 0.1355 mole) in THF (470 ml) was hydrogenated at ca 5 psi in the presence of 10% Pd/C (15.1 g) until completion (ca 40 mins). The mixture was filtered through Celite and the resultant solution evaporated to an oil. This was dissolved in ether (800 ml) and to it was added t-butylamine (9.91 g, 0.1355 mole). Crystallization occurred after a short time and after two hours at 4° the solid was filtered off, washed with ether and dried in vacuo. Recrystallization from isopropanol/ether afforded 24 g (59%) of white material of >95% purity.

Ir. (major peaks) = 2660, 1626, 1296, 1025, 2530, 1586, 1195, 1000, 1809, 1399, 1093, 898, 1690, 1305, 1048, 743 cm. 477SS Example 4 Preparation of the t-butylamine salt of O-methoxvmethvlclavulanic acid The benzyl ester of 0-methoxymethylclavu.lanic 5 acid (83.3 g, 0.25 mole) was dissolved in THF (1250 ml) and water (20 ml) was added. 10% Pd/C (20 g) was used to catalyse the hydrogenolysis which was carried out under a pressure of 45 psi for 1 hour. The reaction mixture was filtered and t-butylamine (27.2 ml 10 = 18.25 g, 0.25 mole) was added. The solvent was evaporated in vacuo (Buchi) and final traces of water were removed under high vacuum. A thick yellow oil resulted, this was dissolved in the least volume of isopropyl alcohol and was shaken vigorously with 15 anhydrous ether (3000 ml). A precipitate formed; after cooling at 5° for 1 hour this was filtered, washed with ether and dried in vacuo to afford 48 g (62%) of an off-white solid whose nmr spectrum was consistent with required structure. (Purity 79%).

Ir. (major peaks) = 2660, 2530, 1698, 1306, 1038, 1805, 1397, 1101, 1628, 1295, 895, 1588, 1197, 745 cm.

Example 5 Composition a) The active ingredient, lubricant and filler may be blended together, granulated and tabletted on a conventional rotary machine to yield 5000 tablets each containing approximately: t-butylamine O-methylclavulante 125 mg Magnesium stearate 1 mg Microcrystalline cellulose 125 mg b) A composition analogous to that described in a) may be prepared by replacing the t-butylamine O-methylclavulanate with t-butylamine O-ethylclavulante. c) The active ingredients, lubricants and filler may be blended together, granulated and tabletted on a conventional rotary machine to yield 5000 tablets approximately: each containing * Amoxycillin trihydrate 300 mg t-butylamine O-methylclavulanate 125 mg magnesium stearate 3 mg 20 microcrystalline cellulose 125 mg * ( containing equivalent of 250 mg pure free amoxycillin) (These formulations may be prepared under a dry atmosphere if desired, for example at less than 30% relative humidity).

Example 6 Preparation of the Sodium salt of O-methyl clavulanic acid O-methyl clavulanic acid t-butylamine salt (10.9 g) in water (5 ml/gm) was passed down an ion5 exchange column IR 120 Na® form (100 ml wet resin).

Fractions containing the sodium salt were combined and evaporated to dryness at room temperature. The residue was dissolved in acetone (IOO ml) and added with vigorous stirring to ether (1 litre). After stirring 1 hour at ambient temperature the precipitated sodium salt was filtered off, washed with ether and dried in vacuo to yield sodium O-methyl clavulanate (8.2 g) (Purity 87.4% by imidazole assay; moisture 6.2%). Λ7755

Claims (14)

1. A compound of the formula (I): wherein 5 R is a hydrogen atom or a methyl, methoxyl, hydroxy1 2 methyl, or nitrile group; R and R are independently a hydrogen atom or a alkyl, phenyl (C 1 _g) alkyl, phenyl or inertly substituted C^_g alkyl, phenyl (C^_g) alkyl or phenyl group; and R° is C^_g alkyl, phenyl (C^_g) alkyl, 10 phenyl or inertly substituted C^_g alkyl, phenyl (C^_g)alkyl 12 3 or phenyl group; any of said groups R , R , and R being optionally interlinked to form a ring of 5—7 ring atoms.

2. A compound as claimed in claim 1 wherein the salt is derivable from 2-amino-2-methylbutane, 2-amino-2-methyl15 pentane, 2-amino-2-methylhexane, 2-amino-2-methylheptane, 2-amino-2-methyloctane, 3-amino-3-methylpentane, 1-amino-lmethylcyclohexane or 1-amino-spiro-adamantane.

3. A compound as claimed in claim 1 wherein R^ is a 2 3 methyl group, R is a hydrogen atom and R is methyl group. 20

4. The tertiarybutylamine salt of clavulanic acid methyl ether.

5. The tertiarybutylamine salt of clavulanic acid ethyl ether.

6. A compound as claimed in any of claims 1—5 in crystalline form. 5

7. A pharmaceutical composition which comprises a compound as claimed in any of claims 1—6 and a pharmaceutically acceptable carrier.

8. A composition as claimed in claim 7 adapted for oral administration to a human.

9. 10 9. A composition as claimed in claims 7 or 8 in the unit-dose form containing 20 mg to 250 mg of the compound as claimed in any of claims 1—6.

10. A composition as claimed in any of claims 7—9 which also comprises a penicillin or cephalosporin. 15

11. A composition as claimed in claim 10 which comprises amoxycillin.

12. A composition as claimed in claim 11 wherein the amoxycillin is present as amoxycillin trihydrate.

13. A compound as claimed in claim 1, substantially as 20 herein described. 4775S

14. A composition as claimed in claim 7, substantially as herein described.